| . "Statistical aspect of translational and correlative studies in clinical trials.." Chin Clin Oncol. 2016;5(1):11. Pub Med |
| . "Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer.." Clin Cancer Res. 2020;26(1):82-92. Pub Med |
| . "Statistical considerations for analysis of microarray experiments.." Clin Transl Sci. 2011;4(6):466-77. Pub Med |
| . "Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.." J Biopharm Stat. 2014;24(4):817-33. Pub Med |
| . "Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.." J Biopharm Stat. 2019;29(4):625-634. Pub Med |
| . "Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.." J Biopharm Stat. 2019;29(4):685-695. Pub Med |
| . "A counterfactual p-value approach for benefit-risk assessment in clinical trials.." J Biopharm Stat. 2015;25(3):508-24. Pub Med |
| . "A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring.." J Biopharm Stat. 2014;24(2):229-53. Pub Med |
| . "Basic concepts and methods for joint models of longitudinal and survival data.." J Clin Oncol. 2010;28(16):2796-801. Pub Med |
| . "Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012.." J Clin Oncol. 2016;34(33):3992-3999. Pub Med |
| . "Missing data in clinical studies: Issues and methods.." J Clin Oncol. 2012;30(26):3297-303. Pub Med |
| . "Clinical trials data collection: When less is more.." J Clin Oncol. 2010;28(34):5019-21. Pub Med |
| . "Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer.." J Thorac Oncol. 2015;10(7):1099-106. Pub Med |
| . "Toxicity related to radiotherapy dose and targeting strategy: A pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer.." J Thorac Oncol. 2019;14(2):298-303. Pub Med |
| . "Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed.." Lifetime Data Anal. 2013;19(4):513-46. Pub Med |
| . "Use of historical control data for assessing treatment effects in clinical trials.." Pharm Stat. 2014;13(1):41-54. Pub Med |
| . "A practical Bayesian adaptive design incorporating data from historical controls.." Stat Med. 2018;37(27):4054-4070. Pub Med |
| . "Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs.." Stat Med. 2013;32(23):3972-90. Pub Med |
| . "The power prior: Theory and applications.." Stat Med. 2015;34(28):3724-49. Pub Med |
| . "Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group.." Stat Med. 2015;34(14):2181-95. Pub Med |
| . "Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.." Stat Med. 2014;33(27):4715-33. Pub Med |
| . "Assessing temporal agreement between central and local progression-free survival times.." Stat Med. 2015;34(5):844-58. Pub Med |
| . "Subgroup detection and sample size calculation with proportional hazards regression for survival data.." Stat Med. 2017;36(29):4646-4659. Pub Med |
| . "On optimal treatment regimes selection for mean survival time.." Stat Med. 2015;34(7):1169-84. Pub Med |
| . "Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'.." Stat Med. 2015;34(14):2202-3. Pub Med |
| . "Bayesian multivariate skew meta-regression models for individual patient data.." Stat Methods Med Res. 2019;28(10-11):3415-3436. Pub Med |
| . "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.." Comput Methods Programs Biomed. 2019;176():211-223. Pub Med |
| . "Continual reassessment method with regularization in phase I clinical trials.." J Biopharm Stat. 2020;30(6):964-978. Pub Med |
| . "Practical designs for Phase I combination studies in oncology.." J Biopharm Stat. 2016;26(1):150-66. Pub Med |
| . "Selection of the initial design for the two-stage continual reassessment method.." J Biopharm Stat. 2017;27(3):495-506. Pub Med |
| . "Dose-finding designs for trials of molecularly targeted agents and immunotherapies.." J Biopharm Stat. 2017;27(3):477-494. Pub Med |
| . "The rapid enrollment design for Phase I clinical trials.." Stat Med. 2016;35(15):2516-24. Pub Med |
| . "Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.." Biometrics. 2012;68(2):578-86. Pub Med |
| . "Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.." Contemp Clin Trials. 2015;42():9-17. Pub Med |
| . "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?." J Biopharm Stat. 2017;27(3):457-476. Pub Med |
| . "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.." J Biopharm Stat. 2015;25(1):66-88. Pub Med |
| . "Enrollment and stopping rules for managing toxicity requiring long follow-up in phase II oncology trials.." J Biopharm Stat. 2015;25(6):1206-14. Pub Med |
| . "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.." J Biopharm Stat. 2016;26(1):141-9. Pub Med |
| . "Phase II cancer clinical trials with heterogeneous patient populations.." J Biopharm Stat. 2012;22(2):312-28. Pub Med |
| . "Randomized phase II clinical trials.." J Biopharm Stat. 2014;24(4):802-16. Pub Med |
| . "Optimal two-stage log-rank test for randomized phase II clinical trials.." J Biopharm Stat. 2017;27(4):639-658. Pub Med |
| . "Seamless phase IIa/IIb and enhanced dose-finding adaptive design.." J Biopharm Stat. 2016;26(5):912-23. Pub Med |
| . "Phase II cancer clinical trials for biomarker-guided treatments.." J Biopharm Stat. 2018;28(2):256-263. Pub Med |
| . "Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: Exploratory analysis of the REMAGUS02 trial.." J Clin Oncol. 2019;37(8):624-635. Pub Med |
| . "Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies.." J Clin Oncol. 2017;35(25):2885-2892. Pub Med |
| . "Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer.." J Thorac Oncol. 2015;10(7):1099-106. Pub Med |
| . "Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.." Lung Cancer. 2020;141():14-20. Pub Med |
| . "Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.." Stat Med. 2014;33(12):2004-16. Pub Med |
| . "Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.." Stat Med. 2014;33(9):1600-18. Pub Med |
| . "Bayesian probability of success for clinical trials using historical data.." Stat Med. 2015;34(2):249-64. Pub Med |
